The gut microbiome diversity of Clostridioides difficile-inoculated mice treated with vancomycin and fidaxomicin

被引:21
|
作者
Yamaguchi, Tetsuo [1 ]
Konishi, Hiroe [1 ,2 ]
Aoki, Kotaro [1 ]
Ishii, Yoshikazu [1 ]
Chono, Koji [3 ]
Tateda, Kazuhiro [1 ]
机构
[1] Toho Univ, Sch Med, Dept Microbiol & Infect Dis, Tokyo, Japan
[2] Toho Univ, Grad Sch Med, Div Pediat, Tokyo, Japan
[3] Astellas Pharma Inc, Res Portfolio Planning Drug Discovery & Res, Tsukuba, Ibaraki, Japan
关键词
16S rRNA; Clostridioides difficile; Fidaxomicin; Microbiota; RIBOTYPE; 027; MOUSE MODEL; INFECTION; LACTOFERRIN; STRAIN; SUSCEPTIBILITY; EPIDEMIOLOGY; RECURRENCE; PREVENTION; OUTCOMES;
D O I
10.1016/j.jiac.2019.12.020
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objective: To investigate the effect of vancomycin and fidaxomicin on the diversity of intestinal microbiota in a mouse model of Clostridioides difficile infection. Methods: Mice were divided into 11 models (4 mice per model): 6 uninoculated models and 5 models inoculated with C. difficile BI/NAP1/027. Inoculated models were prepared using intraperitoneal clindamycin followed by inoculation with C. difficile BI/NAP1/027. Uninoculated and C. difficile-inoculated mice received 2 or 7 days' vancomycin or fidaxomicin. Clostridium butyricum MIYAIRI 588 probiotic and lactoferrin prebiotic were administered for 10 days to uninoculated mice. Intestinal microbiome composition was investigated by sequence analyses of bacterial 16S rRNA genes from faeces, and microbiota diversity estimated. Results: In uninoculated, untreated ('normal') mice, Clostridia (57.8%) and Bacteroidia (32.4%) accounted for the largest proportions of gut microbiota. The proportion of Clostridia was numerically reduced in C. difficile-inoculated versus normal mice. Administration of vancomycin to C. difficile-inoculated mice reduced the proportions of Bacteroidia and Clostridia, and increased that of Proteobacteria. Administration of fidaxomicin to C. difficile-inoculated mice reduced the proportion of Clostridia to a lesser extent, but increased that of Bacteroidia. Microbiota diversity was lower in C. difficile-inoculated versus normal mice (164.5 versus 349.1 operational taxonomic units (OTUs), respectively); treatment of C. difficile-inoculated mice with 7 days' vancomycin reduced diversity to a greater extent than did 7 days' fidaxomicin treatment (26.2 versus 134.2 OTUs, respectively). Conclusions: Both C. difficile inoculation and treatment with vancomycin or fidaxomicin reduced microbiota diversity; however, dysbiosis associated with fidaxomicin was milder than with vancomycin. (c) 2020 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:483 / 491
页数:9
相关论文
共 50 条
  • [21] REAL-WORLD COMPARATIVE EFFECTIVENESS OF FIDAXOMICIN VS. VANCOMYCIN AMONG MEDICARE BENEFICIARIES WITH CLOSTRIDIOIDES DIFFICILE INFECTION
    Dubberke, Erik R.
    Puckett, Justin T.
    Obi, Engels N.
    Kamal-Bahl, Sachin
    Desai, Kaushal
    Stuart, Bruce
    Doshi, Jalpa A.
    GASTROENTEROLOGY, 2022, 162 (07) : S157 - S157
  • [22] Gut Microbiota Diversity of Preterm Neonates Is Associated With Clostridioides Difficile Colonization
    Couturier, Jeanne
    Lepage, Patricia
    Jolivet, Sarah
    Delannoy, Johanne
    Mesa, Victoria
    Ancel, Pierre-Yves
    Roze, Jean-Christophe
    Butel, Marie-Jose
    Barbut, Frederic
    Aires, Julio
    FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2022, 12
  • [23] Real-World Budget Impact of Fidaxomicin versus Vancomycin or Metronidazole for In-Hospital Treatment of Clostridioides difficile Infection
    Whitney, Laura
    Nesnas, John
    Planche, Timothy
    ANTIBIOTICS-BASEL, 2023, 12 (01):
  • [24] Integrating gut microbiome and host immune markers to understand the pathogenesis of Clostridioides difficile infection
    Ke, Shanlin
    Pollock, Nira R.
    Wang, Xu-Wen
    Chen, Xinhua
    Daugherty, Kaitlyn
    Lin, Qianyun
    Xu, Hua
    Garey, Kevin W.
    Gonzales-Luna, Anne J.
    Kelly, Ciaran P.
    Liu, Yang-Yu
    GUT MICROBES, 2021, 13 (01) : 1 - 18
  • [25] Role of the microbiome in essential metabolism in the human gut and its implications for Clostridioides difficile infection
    Chopra, Teena
    Hylemon, Phil
    Tillotson, Glenn
    OPEN FORUM INFECTIOUS DISEASES, 2023, 10 (09):
  • [26] Comparative Effectiveness of Fidaxomicin vs Vancomycin in Populations With Immunocompromising Conditions for the Treatment of Clostridioides difficile Infection: A Single-Center Study
    Alsoubani, Majd
    Chow, Jennifer K.
    Rodday, Angie Mae
    Kent, David
    Snydman, David R.
    OPEN FORUM INFECTIOUS DISEASES, 2024, 11 (01):
  • [27] Fidaxomicin versus metronidazole, vancomycin and their combination for initial episode, first recurrence and severe Clostridioides difficile infection - An observational cohort study
    Polivkova, Sylvia
    Krutova, Marcela
    Capek, Vaclav
    Sykorova, Blanka
    Benes, Jiri
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2021, 103 : 226 - 233
  • [28] The Role of the Gut Microbiome in Cancer: A Review, With Special Focus on Colorectal Neoplasia and Clostridioides difficile
    Anderson, Sean M.
    Sears, Cynthia L.
    CLINICAL INFECTIOUS DISEASES, 2023, 77 : S471 - S478
  • [29] Oral fidaxomicin versus vancomycin for the treatment of Clostridioides difficile infection: A systematic review and meta-analysis of randomized controlled trials
    Tashiro, Sho
    Mihara, Takayuki
    Sasaki, Moe
    Shimamura, Chiaki
    Shimamura, Rina
    Suzuki, Shiho
    Yoshikawa, Maiko
    Hasegawa, Tatsuki
    Enoki, Yuki
    Taguchi, Kazuaki
    Matsumoto, Kazuaki
    Ohge, Hiroki
    Suzuki, Hiromichi
    Nakamura, Atsushi
    Mori, Nobuaki
    Morinaga, Yoshitomo
    Yamagishi, Yuka
    Yoshizawa, Sadako
    Yanagihara, Katsunori
    Mikamo, Hiroshige
    Kunishima, Hiroyuki
    JOURNAL OF INFECTION AND CHEMOTHERAPY, 2022, 28 (11) : 1536 - 1545
  • [30] The Clinical Effectiveness of Fidaxomicin Compared to Vancomycin in the Treatment of Clostridioides difficile Infection, A Single-Center Real-World Experience
    Alsoubani, Majd
    Chow, Jennifer K.
    Rodday, Angie Mae
    McDermott, Laura A.
    Walk, Seth T.
    Kent, David M.
    Snydman, David R.
    JOURNAL OF INFECTIOUS DISEASES, 2024, 230 (06): : 1501 - 1509